Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Novartis to Comarket Lucentis with Alcon Japan
February 9, 2009
- Updated GL for Colon Cancer to Recommend Bevacizumab, Cetuximab
February 9, 2009
- GSK's 1,200 MRs Start Detailing Adoair for COPD
February 9, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 9, 2009
- 3-Qtr Business Results: 1
February 9, 2009
- Korosho to Study Efficacy of Tamiflu against Resistant Strains
February 9, 2009
- BUSINESS NEWS IN BRIEF
February 9, 2009
- SEMINAR
February 9, 2009
- NHI Societies Asked to More Actively Promote Use of Generics
February 9, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 9, 2009
- Group of Health Insurance Societies to Promote Use of Generics
February 9, 2009
- Risperidone, Olanzapine, Quetiapine Likely to Be Related to Diabetes: AERS DB Analysis
February 9, 2009
- Astellas Proposes Acquisition to CV Therapeutics
February 2, 2009
- JIRA to Demand Digital X-Ray Imaging Fee
February 2, 2009
- Financial Crisis Offers Opportunity for Cash-Rich Biopharma Companies: BCG
February 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 2, 2009
- Hisamitsu to Comarket Fosamac with Banyu
February 2, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 2, 2009
- Wholesalers Have Been Driven Over the Edge: Mr Kimura
February 2, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…